Clinical Trial Detail

NCT ID NCT01900652
Title A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung non-small cell carcinoma

Therapies

Emibetuzumab + Erlotinib

Emibetuzumab

Age Groups: adult senior

No variant requirements are available.